Royce & Associates LP purchased a new stake in shares of Viking Therapeutics Inc (NASDAQ:VKTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 135,000 shares of the biotechnology company’s stock, valued at approximately $1,033,000. Royce & Associates LP owned about 0.19% of Viking Therapeutics at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Viking Therapeutics during the 4th quarter valued at $30,000. Lindbrook Capital LLC purchased a new position in shares of Viking Therapeutics during the 4th quarter valued at $36,000. Quantbot Technologies LP purchased a new position in shares of Viking Therapeutics during the 3rd quarter valued at $109,000. Meeder Asset Management Inc. lifted its position in shares of Viking Therapeutics by 63.5% during the 4th quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 2,839 shares during the last quarter. Finally, First Mercantile Trust Co. purchased a new position in shares of Viking Therapeutics during the 3rd quarter valued at $131,000. 65.69% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Viking Therapeutics stock opened at $7.72 on Friday. The stock has a market cap of $570.25 million, a PE ratio of -9.77 and a beta of 2.73. Viking Therapeutics Inc has a 12 month low of $3.69 and a 12 month high of $24.00.
A number of analysts recently issued reports on VKTX shares. BidaskClub raised Viking Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. William Blair reissued an “outperform” rating on shares of Viking Therapeutics in a report on Thursday. Raymond James dropped their price objective on Viking Therapeutics from $43.00 to $40.00 and set a “strong-buy” rating on the stock in a report on Thursday. Svb Leerink assumed coverage on Viking Therapeutics in a research note on Friday, February 22nd. They issued a “mkt perform” rating on the stock. Finally, Leerink Swann started coverage on Viking Therapeutics in a research note on Friday, February 22nd. They issued a “market perform” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $22.88.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Featured Article: Analyst Ratings Trading
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.